Daewoong Pharmaceutical Signs New Drug Supply Contract Worth 99.2 Billion KRW in Middle East Region

[Asia Economy Reporter Park Jihwan] Daewoong Pharmaceutical announced on the 15th that it has signed an export supply contract for the new drug for gastroesophageal reflux disease, 'Fexuprazan,' with Agras Healthcare for six Middle Eastern countries (Saudi Arabia, United Arab Emirates, Kuwait, Bahrain, Oman, Qatar).

The contract amount is approximately 99.2 billion KRW. Daewoong Pharmaceutical stated, "The drug has not yet received approval in the contracted countries, and exports will proceed after local approval is completed."